Matthew K. Fust, a director at Crinetics Pharmaceuticals ($CRNX), sold shares on the open market once in the last year, totaling about $716,000. His most recent sale occurred on September 26, 2025. These sales rank 5,685th among 11,678 individual insiders in our database, where the average is $8.6 million across about 6.4 transactions. Fust made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sept. 26, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Stock Option (Right to Buy) | 10000 | $0.00 | 2,092.0000 | 92,926,000 | 82.70% | 0.01% |
| Sept. 26, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | S | Common Stock | 16000 | $44.75 | 22,836.0000 | 92,926,000 | 41.20% | 0.02% |
| Sept. 26, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Common Stock | 10000 | $1.91 | 38,836.0000 | 92,926,000 | 34.68% | 0.01% |
| June 11, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Not found | A | Stock Option (right to buy) | 10350 | $0.00 | 10,350.0000 | 92,926,000 | 9999.99% | 0.01% |
| June 11, 2025 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Not found | A | Common Stock | 6900 | $0.00 | 28,836.0000 | 92,926,000 | 31.46% | 0.01% |
| June 10, 2025 | Atara Biotherapeutics, Inc. | $ATRA | Fust Matthew K | Not found | A | Common Stock | 7828 | $0.00 | 18,188.0000 | 7,488,000 | 75.56% | 0.10% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 28571 | $0.00 | 28,571.0000 | 161,978,923 | 9999.99% | 0.02% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 27802 | $0.00 | 27,802.0000 | 161,978,923 | 9999.99% | 0.02% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 161,978,923 | 9999.99% | 0.05% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | D | Stock Option (Right to Buy) | 85586 | $0.00 | 0.0000 | 161,978,923 | 100.00% | 0.05% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | D | Stock Option (Right to Buy) | 27802 | $0.00 | 0.0000 | 161,978,923 | 100.00% | 0.02% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | D | Stock Option (Right to Buy) | 28571 | $0.00 | 0.0000 | 161,978,923 | 100.00% | 0.02% |
| May 28, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 85586 | $0.00 | 85,586.0000 | 161,978,923 | 9999.99% | 0.05% |
| May 15, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 10787 | $0.00 | 10,787.0000 | 90,538,118 | 9999.99% | 0.01% |
| May 15, 2025 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | A | Common Stock | 5740 | $0.00 | 25,945.0000 | 90,538,118 | 28.41% | 0.01% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 27802 | $0.00 | 27,802.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | D | Stock Option (Right to Buy) | 85586 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | D | Stock Option (Right to Buy) | 27802 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | D | Stock Option (Right to Buy) | 28571 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 85586 | $0.00 | 85,586.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2025 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 28571 | $0.00 | 28,571.0000 | 0 | 9999.99% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Common Stock | 2156 | $2.52 | 27,839.0000 | 0 | 8.39% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Common Stock | 3783 | $8.32 | 23,883.0000 | 0 | 18.82% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Common Stock | 1800 | $8.79 | 25,683.0000 | 0 | 7.54% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | S | Common Stock | 7739 | $17.01 | 20,100.0000 | 0 | 27.80% | 0.00% |
| Oct. 18, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Common Stock | 6205 | $8.79 | 26,305.0000 | 0 | 30.87% | 0.00% |
| Oct. 18, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Common Stock | 7844 | $2.52 | 34,149.0000 | 0 | 29.82% | 0.00% |
| Oct. 18, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | S | Common Stock | 14049 | $17.03 | 20,100.0000 | 0 | 41.14% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Stock Option (Right to Buy) | 3783 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Stock Option (Right to Buy) | 1800 | $0.00 | 6,205.0000 | 0 | 22.49% | 0.00% |
| Oct. 17, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Stock Option (Right to Buy) | 2156 | $0.00 | 93,430.0000 | 0 | 2.26% | 0.00% |
| Oct. 18, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Stock Option (Right to Buy) | 6205 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Oct. 18, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | M | Stock Option (Right to Buy) | 7844 | $0.00 | 85,586.0000 | 0 | 8.40% | 0.00% |
| June 18, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 9900 | $0.00 | 9,900.0000 | 73,543,862 | 9999.99% | 0.01% |
| June 18, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | A | Common Stock | 5345 | $0.00 | 20,205.0000 | 73,543,862 | 35.97% | 0.01% |
| June 13, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 28571 | $0.00 | 28,571.0000 | 0 | 9999.99% | 0.00% |
| June 13, 2024 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Common Stock | 20100 | $0.00 | 20,100.0000 | 0 | 9999.99% | 0.00% |
| June 7, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Not found | A | Common Stock | 3400 | $0.00 | 21,936.0000 | 68,175,000 | 18.34% | 0.00% |
| June 7, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Not found | A | Stock Option (right to buy) | 12500 | $0.00 | 12,500.0000 | 68,175,000 | 9999.99% | 0.02% |
| March 31, 2024 | Atara Biotherapeutics, Inc. | $ATRA | Fust Matthew K | Not found | A | Common Stock | 150000 | $0.00 | 259,000.0000 | 4,236,000 | 137.61% | 3.54% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | S | Common Stock | 17500 | $45.50 | 18,536.0000 | 68,175,000 | 48.56% | 0.03% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Stock Option (right to buy) | 12500 | $0.00 | 0.0000 | 68,175,000 | 0.00% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Stock Option (right to buy) | 12500 | $0.00 | 0.0000 | 68,175,000 | 0.00% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Stock Option (right to buy) | 17500 | $0.00 | 0.0000 | 68,175,000 | 0.00% | 0.03% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Stock Option (right to buy) | 17500 | $0.00 | 0.0000 | 68,175,000 | 0.00% | 0.03% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Common Stock | 17500 | $20.23 | 36,036.0000 | 68,175,000 | 94.41% | 0.03% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Common Stock | 12500 | $23.24 | 31,036.0000 | 68,175,000 | 67.44% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | S | Common Stock | 12500 | $43.57 | 18,536.0000 | 68,175,000 | 40.28% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Common Stock | 12500 | $23.23 | 31,036.0000 | 68,175,000 | 67.44% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | S | Common Stock | 12500 | $43.57 | 18,536.0000 | 68,175,000 | 40.28% | 0.02% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | S | Common Stock | 17500 | $43.58 | 18,536.0000 | 68,175,000 | 48.56% | 0.03% |
| March 20, 2024 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | M | Common Stock | 17500 | $18.29 | 36,036.0000 | 68,175,000 | 94.41% | 0.03% |
| March 7, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | S | Common Stock | 2550 | $50.89 | 24,505.0000 | 73,543,862 | 9.43% | 0.00% |
| March 7, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | S | Common Stock | 2145 | $50.85 | 22,360.0000 | 73,543,862 | 8.75% | 0.00% |
| March 7, 2024 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Not found | S | Common Stock | 7500 | $50.88 | 14,860.0000 | 73,543,862 | 33.54% | 0.01% |
| Sept. 14, 2023 | Neumora Therapeutics, Inc. | $NMRA | Fust Matthew K | Not found | A | Stock Option (Right to Buy) | 27802 | $0.00 | 27,802.0000 | 0 | 9999.99% | 0.00% |
| June 16, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | A | Stock Option (right to buy) | 17500 | $0.00 | 17,500.0000 | 0 | 9999.99% | 0.00% |
| June 16, 2023 | Crinetics Pharmaceuticals, Inc. | $CRNX | Fust Matthew K | Director | A | Common Stock | 6000 | $0.00 | 18,536.0000 | 0 | 47.86% | 0.00% |
| June 7, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Director | A | Stock Option (Right to Buy) | 7110 | $0.00 | 7,110.0000 | 69,914,225 | 9999.99% | 0.01% |
| June 7, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Director | A | Common Stock | 3860 | $0.00 | 30,355.0000 | 69,914,225 | 14.57% | 0.01% |
| June 7, 2023 | Ultragenyx Pharmaceutical Inc. | $RARE | Fust Matthew K | Director | D | Common Stock | 3300 | $51.82 | 27,055.0000 | 69,914,225 | 10.87% | 0.00% |
| May 31, 2023 | Atara Biotherapeutics, Inc. | $ATRA | Fust Matthew K | Not found | A | Common Stock | 57000 | $0.00 | 109,000.0000 | 0 | 109.62% | 0.00% |
| May 31, 2023 | Atara Biotherapeutics, Inc. | $ATRA | Fust Matthew K | Not found | A | Non-Qualified Stock Option (Right to Buy) | 79500 | $0.00 | 79,500.0000 | 0 | 9999.99% | 0.00% |